Literature DB >> 16936468

Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing.

Gaetano Antonio Lanza1, Kim Fox, Filippo Crea.   

Abstract

Several cohort studies have shown that increasing heart rate (HR) is a predictor of cardiovascular mortality in apparently healthy subjects, independent of several other potential coronary risk factors. Increased resting HR is also a well-known negative prognostic sign in patients with acute myocardial infarction (MI) and in those with heart failure. The predictive value of HR in MI patients extends at long-term follow-up, is independent of most clinical parameters, including left ventricular function, and seems maintained in the modern era of aggressive reperfusion treatment. In accordance with these data, numerous clinical studies have demonstrated that Beta-blockade, which decreases HR, has significant favorable clinical effects in patients with a history of acute MI or heart failure. Although the unfavorable prognostic effect of HR may reflect the deleterious effect of a sympathovagal imbalance, characterized by sympathetic predominance and vagal depression, several data suggest that HR may by itself cause negative effects on cardiovascular function, inducing an increase in cardiac work and myocardial oxygen consumption and a reduction of the diastolic time, with a reduction of time of myocardial blood supply, both conditions favoring the development of myocardial ischemia, besides facilitating arrhythmias in myocardial ischemic areas, by reentry mechanisms. Thus, a reduction of HR might have direct beneficial clinical effects, as also suggested by experimental findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16936468     DOI: 10.1159/000095401

Source DB:  PubMed          Journal:  Adv Cardiol        ISSN: 0065-2326


  5 in total

1.  Tachycardia, reduced vagal capacity, and age-dependent ventricular dysfunction arising from diminished expression of the presynaptic choline transporter.

Authors:  Brett A English; Martin Appalsamy; Andre Diedrich; Alicia M Ruggiero; David Lund; Jane Wright; Nancy R Keller; Katherine M Louderback; David Robertson; Randy D Blakely
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-07-02       Impact factor: 4.733

Review 2.  Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.

Authors:  Karl-Erik Andersson; Lysanne Campeau; Brian Olshansky
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

Review 3.  Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine.

Authors:  David Feldman; Terry S Elton; Doron M Menachemi; Randy K Wexler
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

4.  A low resting heart rate at diagnosis predicts favourable long-term outcome in pulmonary arterial and chronic thromboembolic pulmonary hypertension. A prospective observational study.

Authors:  Florian F Hildenbrand; Ivan Fauchère; Lars C Huber; Stephan Keusch; Rudolf Speich; Silvia Ulrich
Journal:  Respir Res       Date:  2012-09-03

5.  Synergistic effects of serum uric acid and cardiometabolic risk factors on early stage atherosclerosis: the cardiometabolic risk in Chinese study.

Authors:  Jun Liang; Yanping Li; Na Zhou; Fei Teng; Jing Zhao; Caiyan Zou; Lu Qi
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.